Adalimumab biosimilar - Biocon/Mylan

Drug Profile

Adalimumab biosimilar - Biocon/Mylan

Alternative Names: BMO 2; MYL 1401A

Latest Information Update: 23 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocon
  • Developer Biocon; Mylan
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Eye disorder therapies; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Autoimmune disorders; Plaque psoriasis

Most Recent Events

  • 17 Jul 2018 AbbVie enters into HUMIRA® patent license agreements with Mylan for adalimumab biosimilar in USA and countries where AbbVie owns intellectual property, excluding Europe
  • 01 Mar 2017 Mylan completes a phase III trial in Plaque psoriasis in Bulgaria, Poland, Russia, Ukraine, Germany, Hungary and Estonia (SC) (NCT02714322)
  • 10 Jun 2015 Phase-III clinical trials in Plaque psoriasis in Germany, Hungary (SC) (EudraCT2014-003420-46) after June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top